Patents Assigned to Nektar Therapeutics AL
  • Publication number: 20120195846
    Abstract: A heterobifunctional poly(ethylene glycol) is provided having a hydrolytically degradable linkage, a first terminus comprising an acrylate group, and a second terminus comprising a target such as a protein or pharmaceutical agent or a reactive moiety capable of coupling to a target. Hydrogels can be prepared. The hydrogels can be used as a carrier for a protein or a pharmaceutical agent that can be readily released in a controlled fashion.
    Type: Application
    Filed: April 13, 2012
    Publication date: August 2, 2012
    Applicant: Nektar Therapeutics AL, Corporation
    Inventors: J. Milton Harris, Xuan Zhao
  • Publication number: 20110009589
    Abstract: A heterobifunctional poly(ethylene glycol) is provided having a hydrolytically degradable linkage, a first terminus comprising an acrylate group, and a second terminus comprising a target such as a protein or pharmaceutical agent or a reactive moiety capable of coupling to a target. Hydrogels can be prepared. The hydrogels can be used as a carrier for a protein or a pharmaceutical agent that can be readily released in a controlled fashion.
    Type: Application
    Filed: August 20, 2010
    Publication date: January 13, 2011
    Applicant: Nektar Therapeutics AL., Corporation
    Inventors: J. Milton Harris, Xuan Zhao
  • Publication number: 20100284960
    Abstract: The present invention provides compositions comprising an opioid agonist and a water-soluble, non-peptidic polymer-opioid antagonist conjugate. Among other things, dosage forms and methods of administering the dosage forms are also provided.
    Type: Application
    Filed: November 7, 2007
    Publication date: November 11, 2010
    Applicant: Nektar Therapeutics AL, Corporation
    Inventor: Jennifer Riggs-Sauthier
  • Publication number: 20100210505
    Abstract: Conjugates of a GLP-I moiety may be covalently attached to one or more water-soluble polymers. For instance, a GLP-I polymer conjugate may include a GLP-I moiety releasably attached at its N-terminus to a water-soluble polymer. The GLP-I polymer conjugate may include a GLP-I moiety covalently attached to a water-soluble polymer, wherein the GLP-I moiety possesses an N-methyl substituent. The GLP-I polymer conjugate may include a GLP-I moiety covalently attached at a polymer attachment site to a water-soluble polymer, wherein the GLP-I moiety is glycosylated at a site separate from the polymer attachment site.
    Type: Application
    Filed: December 18, 2006
    Publication date: August 19, 2010
    Applicants: Nektar Therapeutics AL, Corporation, Nektar Therapeutics
    Inventors: Mary J. Bossard, Zhihao Fang, Tacey X. Viegas, Stewart A. Thompson, Mei-chang Kuo
  • Publication number: 20090299050
    Abstract: The invention provides methods for making copolymers and multi-arm block copolymers useful as drug delivery vehicles. The multi-arm block copolymers comprise a central core molecule, such as a residue of a polyol, and at least three copolymer arms covalently attached to the central core molecule, each copolymer arm comprising an inner hydrophobic polymer segment covalently attached to the central core molecule and an outer hydrophilic polymer segment covalently attached to the hydrophobic polymer segment, wherein the central core molecule and the hydrophobic polymer segment define a hydrophobic core region. The solubility of hydrophobic biologically active agents can be improved by entrapment within the hydrophobic core region of the block copolymer. The invention further includes pharmaceutical compositions including such block copolymers, pharmaceutical compositions, and methods of using the block copolymers as drug delivery vehicles.
    Type: Application
    Filed: August 7, 2009
    Publication date: December 3, 2009
    Applicant: Nektar Therapeutics AL, Corporation
    Inventor: Xuan Zhao
  • Publication number: 20090280550
    Abstract: Conjugates of a Factor IX moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided (among other things) are compositions comprising the conjugates, methods of making the conjugates, and methods of administering to a patient compositions comprising the conjugates.
    Type: Application
    Filed: July 8, 2009
    Publication date: November 12, 2009
    Applicant: Nektar Therapeutics AL, Corporation
    Inventors: Mary J. Bossard, Gayle Stephenson
  • Publication number: 20090264600
    Abstract: A method is provided for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid or ester thereof. The method involves the hydrolyzing an ortho ester of a water-soluble polymer so as provide the corresponding acid. In addition, the invention provides water-soluble polymers bearing a terminal carboxylic acid or ester thereof, intermediates and reagents useful in carrying out the method, as well as gels, pharmaceutical formulations, conjugates related to the described water-soluble polymer derivatives.
    Type: Application
    Filed: July 1, 2009
    Publication date: October 22, 2009
    Applicant: Nektar Therapeutics AL, Corporation
    Inventor: Antoni Kozlowski
  • Publication number: 20090234070
    Abstract: The present invention is directed to alkanal derivatives of water-soluble polymers such as poly(ethylene glycol), their corresponding hydrates and acetals, and to methods for preparing and using such polymer alkanals. The polymer alkanals of the invention are prepared in high purity and exhibit storage stability.
    Type: Application
    Filed: January 28, 2009
    Publication date: September 17, 2009
    Applicant: Nektar Therapeutics Al, Corporation
    Inventor: Antoni Kozlowski
  • Patent number: 7589157
    Abstract: The invention provides methods for making copolymers and multi-arm block copolymers useful as drug delivery vehicles. The multi-arm block copolymers comprise a central core molecule, such as a residue of a polyol, and at least three copolymer arms covalently attached to the central core molecule, each copolymer arm comprising an inner hydrophobic polymer segment covalently attached to the central core molecule and an outer hydrophilic polymer segment covalently attached to the hydrophobic polymer segment, wherein the central core molecule and the hydrophobic polymer segment define a hydrophobic core region. The solubility of hydrophobic biologically active agents can be improved by entrapment within the hydrophobic core region of the block copolymer. The invention further includes pharmaceutical compositions including such block copolymers, pharmaceutical compositions, and methods of using the block copolymers as drug delivery vehicles.
    Type: Grant
    Filed: August 21, 2007
    Date of Patent: September 15, 2009
    Assignee: Nektar Therapeutics AL, Corporation
    Inventor: Xuan Zhao
  • Publication number: 20090221766
    Abstract: A synthetic method is provided, wherein the method comprises stereoselectively reducing a ketone of a morphinone to form a reduced morphinone and optionally covalently attaching a water soluble polymer to the reduced morphinone.
    Type: Application
    Filed: April 19, 2007
    Publication date: September 3, 2009
    Applicant: Nektar Therapeutics AL, Corporation
    Inventors: Lin Cheng, Michael D. Bentley
  • Publication number: 20090215988
    Abstract: PEG and related polymer derivatives having weak, hydrolytically unstable linkages near the reactive end of the polymer are provided for conjugation to drugs, including proteins, enzymes, small molecules, and others. These derivatives provide a sufficient circulation period for a drug-PEG conjugate, followed by hydrolytic breakdown of the conjugate and release of the bound molecule. In some cases, drugs that demonstrate reduced activity when permanently coupled to PEG maintain a therapeutically suitable activity when coupled to a degradable PEG in accordance with the invention. The PEG derivatives of the invention can be used to impart improved water solubility, increased size, a slower rate of kidney clearance, and reduced immunogenicity to a conjugate formed by attachment thereto. Controlled hydrolytic release of the bound molecule into an aqueous environment can then enhance the drug's delivery profile by providing a delivery system which employs such polymers and utilizes the teachings provided herein.
    Type: Application
    Filed: March 30, 2009
    Publication date: August 27, 2009
    Applicant: Nektar Therapeutics AL, Corporation
    Inventor: J. Milton Harris
  • Publication number: 20090215910
    Abstract: The invention provides a method for preparing a 1-benzotriazolylcarbonate ester of a water-soluble and non-peptidic polymer by reacting a terminal hydroxyl group of a water-soluble and non-peptidic polymer with di(1-benzotriazolyl)carbonate in the presence of an amine base and an organic solvent. The polymer backbone can be poly(ethylene glycol). The 1-benzotriazolylcarbonate ester can then be reacted directly with a biologically active agent to form a biologically active polymer conjugate or reacted with an amino acid, such as lysine, to form an amino acid derivative.
    Type: Application
    Filed: April 30, 2009
    Publication date: August 27, 2009
    Applicant: Nektar Therapeutics AL, Corporation
    Inventor: Antoni Kozlowski
  • Patent number: 7579444
    Abstract: Conjugates of a Factor IX moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided (among other things) are compositions comprising the conjugates, methods of making the conjugates, and methods of administering to a patient compositions comprising the conjugates.
    Type: Grant
    Filed: June 30, 2005
    Date of Patent: August 25, 2009
    Assignee: Nektar Therapeutics AL, Corporation
    Inventors: Mary J. Bossard, Gayle Stephenson
  • Patent number: 7569214
    Abstract: A method is provided for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid or ester thereof. The method involves the hydrolyzing an ortho ester of a water-soluble polymer so as provide the corresponding acid. In addition, the invention provides water-soluble polymers bearing a terminal carboxylic acid or ester thereof, intermediates and reagents useful in carrying out the method, as well as gels, pharmaceutical formulations, conjugates related to the described water-soluble polymer derivatives.
    Type: Grant
    Filed: September 9, 2003
    Date of Patent: August 4, 2009
    Assignee: Nektar Therapeutics AL, Corporation
    Inventor: Antoni Kozlowski
  • Publication number: 20090186984
    Abstract: An activated, substantially water-soluble poly(ethylene glycol) is provided having of a linear or branched poly(ethylene glycol) backbone and at least one terminus linked to the backbone through a hydrolytically stable linkage, wherein the terminus is branched and has proximal reactive groups. The free reactive groups are capable of reacting with active moieties in a biologically active agent such as a protein or peptide thus forming conjugates between the activated (polyethylene glycol) and the biologically active agent.
    Type: Application
    Filed: March 24, 2009
    Publication date: July 23, 2009
    Applicant: Nektar Therapeutics AL, Corporation
    Inventors: J. Milton Harris, Antoni Kozlowski
  • Patent number: 7547509
    Abstract: The present invention provides variants of cyanovirin-N and water-soluble polymer conjugates thereof, and methods of preparing such conjugates. The cyanovirin-N of the invention are particularly suited for site-selective covalent attachment of one or more water soluble polymers, to provide polymer conjugates of cyanovirin-N variants exhibiting antiviral activity.
    Type: Grant
    Filed: August 2, 2007
    Date of Patent: June 16, 2009
    Assignees: Nektar Therapeutics AL, Corporation, National Institute of Heatlh
    Inventors: M. Elizabeth Snell, Michael J. Roberts, Toshiyuki Mori, Barry R. O'Keefe, Michael R. Boyd
  • Patent number: 7544738
    Abstract: The invention provides a method for preparing a 1-benzotriazolylcarbonate ester of a water-soluble and non-peptidic polymer by reacting a terminal hydroxyl group of a water-soluble and non-peptidic polymer with di(1-benzotriazolyl)carbonate in the presence of an amine base and an organic solvent. The polymer backbone can be poly(ethylene glycol). The 1-benzotriazolylcarbonate ester can then be reacted directly with a biologically active agent to form a biologically active polymer conjugate or reacted with an amino acid, such as lysine, to form an amino acid derivative.
    Type: Grant
    Filed: April 25, 2008
    Date of Patent: June 9, 2009
    Assignee: Nektar Therapeutics AL, Corporation
    Inventor: Antoni Kozlowski
  • Patent number: 7528202
    Abstract: An activated, substantially water-soluble poly(ethylene glycol) is provided having of a linear or branched poly(ethylene glycol) backbone and at least one terminus linked to the backbone through a hydrolytically stable linkage, wherein the terminus is branched and has proximal reactive groups. The free reactive groups are capable of reacting with active moieties in a biologically active agent such as a protein or peptide thus forming conjugates between the activated (polyethylene glycol) and the biologically active agent.
    Type: Grant
    Filed: April 30, 2007
    Date of Patent: May 5, 2009
    Assignee: Nektar Therapeutics AL, Corporation
    Inventors: J. Milton Harris, Antoni Kozlowski
  • Patent number: 7511095
    Abstract: The invention provides reagents and methods for conjugating a polymer specifically to the ?-amine of a polypeptide. The invention provides monofunctional, bifunctional, and multifunctional PEGs and related polymers having a terminal thioester moiety capable of specifically conjugating to the ?-amine of a polypeptide having a cytokine or histidine residue at the N-terminus. The invention provides reactive thioester-terminated PEG polymers that have suitable reactivity with an N-terminal cysteine or histidine residue of a polypeptide to produce an amide bond between the PEG molecule and the polypeptide.
    Type: Grant
    Filed: February 13, 2006
    Date of Patent: March 31, 2009
    Assignee: Nektar Therapeutics AL, Corporation
    Inventors: Michael J. Roberts, Zhihao Fang
  • Patent number: 7511094
    Abstract: The present invention is directed to alkanal derivatives of water-soluble polymers such as poly(ethylene glycol), their corresponding hydrates and acetals, and to methods for preparing and using such polymer alkanals. The polymer alkanals of the invention are prepared in high purity and exhibit storage stability.
    Type: Grant
    Filed: March 13, 2006
    Date of Patent: March 31, 2009
    Assignee: Nektar Therapeutics AL, Corporation
    Inventor: Antoni Kozlowski